Sophia Chen,Marcel R M van den Brink
Sophia Chen
Chimeric antigen receptor (CAR) T cell therapy has shown impressive clinical efficacy in B cell malignancies and multiple myeloma, leading to the approval of six CAR T cell products by the U.S. Food and Drug Administration (FDA) to date. Ho...
Cytomegalovirus in haematopoietic cell transplantation - The troll is still there [0.03%]
造血干细胞移植中的巨细胞病毒——依然存在的威胁
Sebastian Voigt
Sebastian Voigt
Patients undergoing allogeneic haematopoietic cell transplantation are prone to complications caused by viral infections. Cytomegalovirus (CMV) considerably impacts transplantation as it frequently requires antiviral intervention that evoke...
Effie W Petersdorf
Effie W Petersdorf
The degree of HLA compatibility between a patient and donor has formed the basis of donor selection since the development of allogeneic hematopoietic cell transplantation over 50 years ago and has advanced understanding of the basic immunob...
Gregorio Jaimovich,Robert Peter Gale
Gregorio Jaimovich
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT? [0.03%]
HLA-E及其受体是allo-HCT中的免疫检查点还是抗原决定簇？
Hana Rohn,Vera Rebmann
Hana Rohn
Hematopoietic cell transplantation (HCT) represents a potentially curative therapeutic approach for various hematologic and non-hematologic malignancies. Human leukocyte antigen (HLA) matching is still the central selection criterion for HC...
Alicia Sanchez-Mazas,José Manuel Nunes;PGAE HLA Consortium of the th International HLA and Immunogenetics Workshop
Alicia Sanchez-Mazas
A comprehensive knowledge of human leukocyte antigen (HLA) molecular variation worldwide is essential in human population genetics research and disease association studies and is also indispensable for clinical applications such as allogene...
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation [0.03%]
allo-HSCT后TCR-.repertoire的形成规律
Heike Uhlemann,Katharina Epp,Christian Klesse et al.
Heike Uhlemann et al.
The human adaptive immune repertoire is characterized by specificity and diversity to provide immunity against past and future tasks. Such tasks are mainly infections but also malignant transformations of cells. With its multiple lines of d...
Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation [0.03%]
allo-HSCT后预测、监测或操纵GvL和GvHD的次要组织相容性抗原
Kyra J Fuchs,J H Frederik Falkenburg,Marieke Griffioen
Kyra J Fuchs
Allogeneic hematopoietic cell transplantation (alloHCT) provides a potential curative treatment for haematological malignancies. The therapeutic Graft-versus-Leukaemia (GvL) effect is induced by donor T cells attacking patient hematopoietic...
Corrigendum to "HIV-associated lymphoma" [Best Pract Res Clin Haematol 25 (2012) 101-117] [0.03%]
“与艾滋病相关的淋巴瘤”一文的勘误通知（最佳实践和研究：血液病学卷25期（2012年）101-117页）
Lawrence D Kaplan
Lawrence D Kaplan
HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia [0.03%]
HLA-DM和HLA-DO在健康组织和白血病中对II类HLA肽编辑的相互作用
Bettina Budeus,Miguel Álvaro-Benito,Pietro Crivello
Bettina Budeus
HLA class II antigen presentation is modulated by the activity of the peptide editor HLA-DM and its antagonist HLA-DO, with their interplay controlling the peptide repertoires presented by normal and malignant cells. The role of these molec...